Meeting
2018 ASCO Annual Meeting
EGFR reporting in stage IV adenocarcinoma of the lung: Demographic predictors of EGFR testing and survival.
Authors
Shagufta Shaheen
Loma Linda University Medical Center, Loma Linda, CA
Shagufta Shaheen , Liang Ji , Hamid Mirshahidi , Salman Otoukesh , Gayathri Nagaraj , Saied Mirshahidi , John W Morgan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9100)
DOI
10.1200/JCO.2018.36.15_suppl.9100
Abstract #
9100
Poster Bd #
423
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Clinical, pathological and genetic predictors of patient-derived xenograft (PDX) engraftment in EGFR-mutated lung adenocarcinoma (LUAD).
First Author: Sebastiao N. Martins-Filho
Poster
2019 ASCO Annual Meeting
The tumor microenvironment in EGFR-driven loco-regional lung adenocarcinoma can predict higher risk of recurrence.
First Author: Maya Khalil
Poster
2014 ASCO Annual Meeting
Significance of the estrogen signaling pathway in EGFR wild-type lung adenocarcinoma.
First Author: Kazumi Tanaka
Poster
2013 ASCO Annual Meeting
Occurrence of HER2 amplification in EGFR-mutant lung adenocarcinoma with acquired resistence to EGFR-TKIs.
First Author: Giuseppe Altavilla